Role of the microenvironment in multiple myeloma bone disease

Alissa Huston, G. David Roodman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Multiple myeloma bone disease occurs in over 70-80% of patients with myeloma and represents a significant source of morbidity and mortality. Early in multiple myeloma bone disease there is a balance between osteoclast activation and osteoblast suppression. However, this balance appears to be lost in advanced disease, resulting in the development of lytic lesions and bone destruction. Osteoclast activation occurs through a variety of factors, including receptor activator of nuclear factor-κB ligand, macrophage inflammatory protein-1α, interleukin-3 and interleukin-6, resulting in osteoclast stimulation and bone resorption. There is also significant osteoblast suppression through the inhibitory actions of interleukin-3, dickkopf 1, secreted frizzled-related protein-2 and interleukin-7. Understanding the mechanisms behind myeloma bone disease will help to identify potential future therapeutic interventions to help ameliorate or prevent osteoblast suppression and decrease osteoclast activation, with the goal of improving the overall quality of life for patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)371-378
Number of pages8
JournalFuture Oncology
Volume2
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Bone Diseases
Osteoclasts
Multiple Myeloma
Osteoblasts
Interleukin-3
Macrophage Inflammatory Proteins
Interleukin-7
Bone Resorption
Cytoplasmic and Nuclear Receptors
Interleukin-6
Quality of Life
Ligands
Morbidity
Bone and Bones
Mortality
Therapeutics

Keywords

  • Dickkopf 1
  • Inflammatory metastatic bone disease
  • Interleukin-3
  • Interleukin-7
  • Macrophage
  • Multiple myeloma
  • Osteoblast
  • Osteoclast
  • Protein-1α
  • Receptor activator of NF-κB ligand
  • Secreted frizzled-related protein-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Role of the microenvironment in multiple myeloma bone disease. / Huston, Alissa; Roodman, G. David.

In: Future Oncology, Vol. 2, No. 3, 06.2006, p. 371-378.

Research output: Contribution to journalArticle

@article{1aef13171a40418a92263dfe31edee5a,
title = "Role of the microenvironment in multiple myeloma bone disease",
abstract = "Multiple myeloma bone disease occurs in over 70-80{\%} of patients with myeloma and represents a significant source of morbidity and mortality. Early in multiple myeloma bone disease there is a balance between osteoclast activation and osteoblast suppression. However, this balance appears to be lost in advanced disease, resulting in the development of lytic lesions and bone destruction. Osteoclast activation occurs through a variety of factors, including receptor activator of nuclear factor-κB ligand, macrophage inflammatory protein-1α, interleukin-3 and interleukin-6, resulting in osteoclast stimulation and bone resorption. There is also significant osteoblast suppression through the inhibitory actions of interleukin-3, dickkopf 1, secreted frizzled-related protein-2 and interleukin-7. Understanding the mechanisms behind myeloma bone disease will help to identify potential future therapeutic interventions to help ameliorate or prevent osteoblast suppression and decrease osteoclast activation, with the goal of improving the overall quality of life for patients with multiple myeloma.",
keywords = "Dickkopf 1, Inflammatory metastatic bone disease, Interleukin-3, Interleukin-7, Macrophage, Multiple myeloma, Osteoblast, Osteoclast, Protein-1α, Receptor activator of NF-κB ligand, Secreted frizzled-related protein-2",
author = "Alissa Huston and Roodman, {G. David}",
year = "2006",
month = "6",
doi = "10.2217/14796694.2.3.371",
language = "English (US)",
volume = "2",
pages = "371--378",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Role of the microenvironment in multiple myeloma bone disease

AU - Huston, Alissa

AU - Roodman, G. David

PY - 2006/6

Y1 - 2006/6

N2 - Multiple myeloma bone disease occurs in over 70-80% of patients with myeloma and represents a significant source of morbidity and mortality. Early in multiple myeloma bone disease there is a balance between osteoclast activation and osteoblast suppression. However, this balance appears to be lost in advanced disease, resulting in the development of lytic lesions and bone destruction. Osteoclast activation occurs through a variety of factors, including receptor activator of nuclear factor-κB ligand, macrophage inflammatory protein-1α, interleukin-3 and interleukin-6, resulting in osteoclast stimulation and bone resorption. There is also significant osteoblast suppression through the inhibitory actions of interleukin-3, dickkopf 1, secreted frizzled-related protein-2 and interleukin-7. Understanding the mechanisms behind myeloma bone disease will help to identify potential future therapeutic interventions to help ameliorate or prevent osteoblast suppression and decrease osteoclast activation, with the goal of improving the overall quality of life for patients with multiple myeloma.

AB - Multiple myeloma bone disease occurs in over 70-80% of patients with myeloma and represents a significant source of morbidity and mortality. Early in multiple myeloma bone disease there is a balance between osteoclast activation and osteoblast suppression. However, this balance appears to be lost in advanced disease, resulting in the development of lytic lesions and bone destruction. Osteoclast activation occurs through a variety of factors, including receptor activator of nuclear factor-κB ligand, macrophage inflammatory protein-1α, interleukin-3 and interleukin-6, resulting in osteoclast stimulation and bone resorption. There is also significant osteoblast suppression through the inhibitory actions of interleukin-3, dickkopf 1, secreted frizzled-related protein-2 and interleukin-7. Understanding the mechanisms behind myeloma bone disease will help to identify potential future therapeutic interventions to help ameliorate or prevent osteoblast suppression and decrease osteoclast activation, with the goal of improving the overall quality of life for patients with multiple myeloma.

KW - Dickkopf 1

KW - Inflammatory metastatic bone disease

KW - Interleukin-3

KW - Interleukin-7

KW - Macrophage

KW - Multiple myeloma

KW - Osteoblast

KW - Osteoclast

KW - Protein-1α

KW - Receptor activator of NF-κB ligand

KW - Secreted frizzled-related protein-2

UR - http://www.scopus.com/inward/record.url?scp=33745508154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745508154&partnerID=8YFLogxK

U2 - 10.2217/14796694.2.3.371

DO - 10.2217/14796694.2.3.371

M3 - Article

VL - 2

SP - 371

EP - 378

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -